American Journal of Psychiatry

Volume 2016
Number 1
August 2016

Articles

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia

George M. Haig, Pharm.D., M.B.A.,
Earle E. Bain, M.D.,
Weining Z. Robieson, Ph.D.,
Jeffrey D. Baker, Ph.D.,
Ahmed A. Othman, Ph.D.

Publication date: 01 August 2016

Pages827–835

Objective: The authors sought to evaluate the efficacy and safety of ABT-126, a selective α7 nicotinic receptor partial agonist, in stable patients with schizophrenia. Method: A 12-week, double-blind, placebo-controlled, parallel-group phase 2 study was ...

https://doi.org/10.1176/appi.ajp.2015.15010093.2016.1.test